Loading patent…
AssigneeCue Biopharma, Inc.
InventorsRonald D. SEIDEL, III, Rodolfo CHAPARRO, John F. ROSS, Chee Meng LOW
Estimating the term…
The present disclosure provides T-cell modulatory multimeric polypeptide epitope conjugates comprising an immunomodulatory polypeptide (“MOD”) that may be selected to exhibit reduced binding affinity to a cognate co-immunomodulatory polypeptide (“Co-MOD”) and a conjugated Wilms tumor-1 (WT-1) epitope presenting peptide. The T-Cell-MMP-epitope conjugates are useful for modulating the activity of a T-cell by delivering immunomodulatory peptides, such as IL-2 or IL-2 variants that exhibit reduced binding affinity for IL-2R, to the T-cells in a WT-1 epitope selective/specific manner, and accordingly, for treating individuals, particularly those with acute myeloid leukemia, myeloma, ovarian cancer, pancreatic cancer, non-small cell lung cancer, colorectal cancer, breast cancer, Wilms tumor, mesothelioma, soft tissue sarcoma, neuroblastoma, or nephroblastoma.
A T-cell modulatory multimeric polypeptide epitope conjugate (T-Cell-MMP-epitope conjugate) or a dimer of T-Cell-MMP-epitope conjugates, wherein each T-Cell-MMP-epitope conjugate comprises:
A T-cell modulatory multimeric polypeptide epitope conjugate (T-Cell-MMP-epitope conjugate) or a dimer of T-Cell-MMP-epitope conjugates, wherein each T-Cell-MMP-epitope conjugate comprises:
A T-cell modulatory multimeric polypeptide epitope conjugate (T-Cell-MMP-epitope conjugate) or a dimer of T-Cell-MMP-epitope conjugates, wherein each T-Cell-MMP-epitope conjugate comprises:
6-7. (canceled)
(canceled)
(canceled)
18-19. (canceled)
25-26. (canceled)
Dependencies are inferred from the claim text.